Cardiovascular Medicine

3 pages, 502 KB

Open AccessEditorial

Cardiology Update 20 India – an Educational Online Programme of the Zurich Heart House

by Thomas F. Lüscher

Cardiovasc. Med. 2021, 24(5), w02131; https://doi.org/10.4414/cvm.2021.02131 - 15 Sep 2021

During the COVID-19 pandemic postgraduate education is quite challenging, as face-to-face meetings are prohibited, particularly where infection rates are high.[...] Full article

► Show Figures

Figure 1

6 pages, 575 KB

Open AccessReview

Dyslipidaemia and Hypertension – Brothers in Crime?!

by Darko Minoski and Thomas Dieterle

Cardiovasc. Med. 2021, 24(5), w10090; https://doi.org/10.4414/cvm.2021.02177 - 1 Sep 2021

Abstract

Cardiovascular disease (CVD) remains the major cause of mortality and healthcare costs worldwide [...] Full article

4 pages, 8496 KB

Open AccessInteresting Images

When the Chest Pain Suddenly Worsens

by Jana Balcova and Philippe N Müller

Cardiovasc. Med. 2021, 24(5), 2184; https://doi.org/10.4414/cvm.2021.02184 - 1 Sep 2021

Viewed by 61

Abstract

A 76-year-old male presented to the emergency room with a sudden progression of chronic intermittent retrosternal chest pain for 2 hours [...] Full article

► Show Figures

Figure 1

2 pages, 4449 KB

Open AccessCase Report

A Rare Cause of Acute Coronary Syndrome

by Barbara Pitta Gros, Nathalie Sala and Christan Roguelov

Cardiovasc. Med. 2021, 24(5), 2182; https://doi.org/10.4414/cvm.2021.02182 - 1 Sep 2021

Viewed by 58

Abstract

The authors present a case of acute coronary syndrome caused by a covered rupture of the aorta compressing the left main coronary artery. The cause of the rupture was later revealed to be a giant cell aortitis in a patient who had no [...] Read more.

The authors present a case of acute coronary syndrome caused by a covered rupture of the aorta compressing the left main coronary artery. The cause of the rupture was later revealed to be a giant cell aortitis in a patient who had no other symptoms and was not known for giant cell arteritis. Full article

► Show Figures

Figure 1

6 pages, 6840 KB

Open AccessCase Report

A Case Series of Acute Myocarditis Associated with SARS-CoV-2 mRNA Vaccination

by Christophe Abellan, Hari Vivekanantham, Allal Mahmoudi, Stéphane Cook, Sébastien Doll and Diego Arroyo

Cardiovasc. Med. 2021, 24(5), 2181; https://doi.org/10.4414/cvm.2021.02181 - 1 Sep 2021

Cited by 3 | Viewed by 51

Abstract

We present three cases of patients who devel-oped acute, non-severe myocarditis following messenger RNA-1273 vaccine from Moderna (Moderna Inc.) against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A brief review of the literature, diagnostic modalities, work-up and treatment are discussed. Full article

► Show Figures

Figure 1

8 pages, 6264 KB

Open AccessReview

Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Over Time: One Size Does Not Fit All

by Stjepan Jurisic, Dimitri Patriki and Jürg H. Beer

Cardiovasc. Med. 2021, 24(5), 155; https://doi.org/10.4414/cvm.2021.02175 - 1 Sep 2021

Viewed by 73

Abstract

Dual antiplatelet therapy (DA PT) is the evidence-based standard of care in patients with acute coronary syndrome (ACS) managed invasively or noninvasively, as well as for secondary prevention of coronary artery disease (CAD). The optimal treatment duration and composition of DA PT, however, [...] Read more.

Dual antiplatelet therapy (DA PT) is the evidence-based standard of care in patients with acute coronary syndrome (ACS) managed invasively or noninvasively, as well as for secondary prevention of coronary artery disease (CAD). The optimal treatment duration and composition of DA PT, however, remains a major challenge. Very low-dose (VLD) anticoagulation with rivaroxaban combined with antiplatelet therapy showed better outcomes in patients with ACS or stable CAD who were at high risk for ischaemic events and low bleeding risk. Current guidelines highlight patient risk stratification to individualise DA PT composition and duration. These personalised risk assessments, and implications for ischaemic events and bleeding complications are essential in decision making for adequate antithrombotic therapy and treatment decisions. Full article

► Show Figures

Figure 1

3 pages, 5341 KB

Open AccessEditorial

The Last Impact Factor of the European Heart Journal for the Zurich Team: A Farewell with Pride!

by Thomas F. Lüscher

Cardiovasc. Med. 2021, 24(5), 10104; https://doi.org/10.4414/cvm.2021.02252 - 1 Sep 2021

Viewed by 57

Abstract

The Zurich team, with an amazing editorial staff at the Zurich Heart House and excellent editors covering the entire spectrum of cardiovascular medicine from Europe, USA and Asia, took over the European Heart Journal from Frans von de Werf in 2009 with an [...] Read more.

The Zurich team, with an amazing editorial staff at the Zurich Heart House and excellent editors covering the entire spectrum of cardiovascular medicine from Europe, USA and Asia, took over the European Heart Journal from Frans von de Werf in 2009 with an impact factor of 8.7, bi-weekly issues only, but in good shape [...] Full article

► Show Figures

Figure 1

2 pages, 532 KB

Open AccessInteresting Images

Transradial Coronary Angiography: The Right Path Less Travelled

by Andreas Y. Andreou, Lida Efstathia Koskina, Abdul-Adl Opemipo Bolaji and Daniela Toumazi

Cardiovasc. Med. 2021, 24(5), 10094; https://doi.org/10.4414/cvm.2021.02253 - 1 Sep 2021

Viewed by 64

Abstract

A 46-year-old male smoker, with a positive family history of premature coronary artery disease and a history of arterial hypertension and hyperlipidaemia was referred for coronary angiography because of episodes of stabbing precordial chest pain elicited by psychological stress and dyspnoea for the [...] Read more.

A 46-year-old male smoker, with a positive family history of premature coronary artery disease and a history of arterial hypertension and hyperlipidaemia was referred for coronary angiography because of episodes of stabbing precordial chest pain elicited by psychological stress and dyspnoea for the last 2 months [...] Full article

► Show Figures

Figure 1

1 pages, 243 KB

Open AccessEditorial

2021 Hypertension Best Publication Award of the Swiss Society of Hypertension

by Swiss Society of Hypertension

Cardiovasc. Med. 2021, 24(5), 10091; https://doi.org/10.4414/cvm.2021.02251 - 1 Sep 2021

Viewed by 51

Abstract

The Swiss Society of Hypertension (SSH) has the privilege to announce the first Publication Award of the SSH [...] Full article

824 KB

Open AccessCase Report

Re-Re-Re-Operation bei Graftausriss der Aorten-Prothese: Stellenwert regelmässiger Nachkontrollen

by Mönkediek Frederik, Eckstein Friedrich S., Schurr Ulrich, Zuber Michel and Koechlin Luca

Cardiovasc. Med. 2021, 24(5), w02135; https://doi.org/10.4414/cvm.2021.02135 - 9 Sep 2020

Abstract

After intervention on the thoracic aorta, various early and late complications can occur. Here we present the case of a 63-year-old patient with a false aortic aneurysm 17 years after the last aortic surgery, stressing the importance of life-long follow-up. Full article

► Show Figures

Figure 1

Journal Menu

Journal Browser

Cardiovasc. Med., Volume 24, Issue 5 (09 2021) – 10 articles

Further Information

Guidelines

MDPI Initiatives

Follow MDPI